Age-related macular degeneration: A review of anti-angiogenic treatments;Traitements anti-angiogéniques au cours de la dégénérescence maculaire liée à l'âge

Journal Francais d'Ophtalmologie

Volumn 25, Issue 7, 2002, Pages 747-752

  Razavi, S ^a   Coscas, G ^a   Soubrane, G ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

Age related macular degeneration; Anti angiogenic treatment; Choroidal neovascular membrane; Pharmacological therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; APTAMER; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; INTEGRIN; INTEGRIN INHIBITOR; LIPOSOME; MATRIX METALLOPROTEINASE INHIBITOR; THALIDOMIDE; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGED; CLINICAL TRIAL; CONSTIPATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; LASER COAGULATION; MEDICAL LITERATURE; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTODYNAMIC THERAPY; RAT; RECURRENT DISEASE; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SOMNOLENCE; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

ADRENAL CORTEX HORMONES; AGED; AGING; ANGIOGENESIS INHIBITORS; HUMANS; MACULAR DEGENERATION;

EID: 17944396283     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Savona C, Javerzat S, Perollet C, Bikfalvi A. Angiogenesis and neoangiogenesis. Rev Prat, 1997;47:2239-43.
2. Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol, 1994;118:445-50.
3. Miller JW. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol, 1997;151:13-23.
4. Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol, 1997;124:521-9.
5. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
6. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci, 1998;39:2194-200.
7. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994;79:1157-64.
8. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994;264:569-71.
9. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer, 1996;32A:2423-9.
10. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science, 1995;270:1500-2.
11. Friedlander M, Theesfeld CL, Sugita M et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A, 1996;93:9764-9.
12. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell, 1992;69:11-25.
13. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A, 1994;91:4082-5.
14. Miller MT, Stromland K. Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses. Teratology, 1999;60:306-21.
15. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol, 1998;236:461-6.
16. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci, 1997;38:36-47.
17. Frank RN. Growth factors in age-related macular degeneration: Pathogenic and therapeutic implications. Ophthalmic Res, 1997;29:341-53.
18. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci, 1996;37:855-68.
19. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci, 1994;35:3178-88.
20. Soubrane G, Cohen SY, Delayre T et al. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr Eye Res, 1994;13:183-95.
21. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol, 1995;113:1538-44.
22. Pournaras CJ, Miller JW, Gragoudas ES et al. Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol, 1997;115:1553-8.
23. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A, 1995;92:10457-61.
24. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med, 1996;2:529-33.
25. Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim, 1999;35:533-42.
26. Drolet DW, Nelson J, Tucker CE et al. Pharmacokinetics and safety of an antivascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res, 2000;17:1503-10.
27. Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol, 1999;117:498-503.
28. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina, 2000;20:244-50.
29. BenEzra D, Griffin BW, Maftzir G, Sharif NA, Clark AF. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci, 1997;38:1954-62.
30. McNatt LG, Weimer L, Yanni J, Clark AF. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther, 1999;15:413-23.
31. Clark AF, Mellon J, Li XY et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anécortave acetate. Invest Ophthalmol Vis Sci, 1999;40:2158-62.
32. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci, 2001;42:283-90.
33. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab Invest, 1996;75:563-73.
34. Preissner KT, Kanse SM, Hammes HP. Integrin chatter and vascular function in diabetic retinopathy. Horm Metab Res, 1997;29:643-5.
35. Brooks PC, Stromblad S, Sanders LC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell, 1996;85:683-93.
36. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 1994;79:315-28.
37. Shin SH, Kim JC, Chang SI, Lee H, Chung SI. Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. Cornea, 2000;19:212-7.
38. Kim JH, Kim JC, Shin SH, Chang SI, Lee HS, Chung SI. The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Exp Mol Med, 1999;31:203-9.
39. Renno RZ, Delori FC, Holzer RA, Gragoudas ES, Miller JW. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci, 2000;41:3963-71.
40. Behar-Cohen FF, Parel JM, Pouliquen Y et al. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res, 1997;65:533-45.
41. Ambati J, Gragoudas ES, Miller JW et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci, 2000;41:1186-91.
42. Ambati J, Canakis CS, Miller JW et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci, 2000;41:1181-5.